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Newer Therapies in Hypercalcemia and Metabolic Bone Disease 
Hunter Heath HI, MD* 
The decade ofthe '80s has been an exciting one for all investi-gators in the area of calcium and bone metabolism because a 
remarkable convergence of technology, basic science applica-
tions, and clinical interest has led to major advances in under-
standing this area. The physiology of calcium-regulating hor-
mone secretion and action, mechanisms of plasma calcium 
homeostasis, the cellular basis of metabolic bone disease—all 
have yielded to concerted attack. However, the practicing physi-
cian has seen much of this advance somewhat from the sidelines, 
asking legitimately when this new information was going to be 
translated into practical measures for care of patients. This ses-
sion was intended to address this justified query and to point out 
several important therapeutic maneuvers that are available now, 
are about to see general use, or represent promising first ap-
proaches to new agents. We focused on three important areas: 
the life-threatening hypercalcemia frequently accompanying 
malignant tumors, aluminum-related renal osteodystrophy, 
and osteoporosis. 
Hypercalcemia of Malignancy 
The pathogenesis of hypercalcemia in malignancy is complex 
and varies among tumor types. The older classification as "ec-
topic parathyroid hormone (PTH)-secreting" versus that caused 
by direct tumor destmction of bone was based on indirect and 
largely mistaken premises. Secretion of authentic PTH by non-
parathyroid tumors has never been convincingly demonstrated, 
and tumor metastases are now known to destroy bone indirectly, 
by stimulating generation and activity of osteoclasts. 
It is now clear that almost all nonparathyroidal malignant 
tumors causing hypercalcemia do so by secreting or inducing 
the formation of factors that in turn stimulate osteoclasts. One 
such tumor product is a 141-amino acid peptide with some PTH-
like structure and bioactivities. This PTH-related pep-
tide (PTHrP) lyses bone but also stimulates renal tubular reab-
sorption of calcium; these two actions may account for the 
viciousness of the ensuing hypercalcemia. Other direct or indi-
rect tumor hypercalcemic substances may include 1,25-
dihydroxyvitamin D, prostaglandins, transforming growth 
factors, and other peptide cytokines. 
Diphosphonate treatment of severe hypercalcemia 
Aside from various antitumor measures, there are no effective 
ways to inhibit secretion of hypercalcemic factors. Thus, treat-
ment ofthe hypercalcemia has focused first on inhibition of os-
teoclasts and second on enhancing renal excretion of calcium. 
Body (1) reviewed agents currently available, then concentrated 
on the biphosphonates (diphosphonates). These synthetic ana-
logs of pyrophosphate are potent inhibitors of bone resorption 
but have varying potencies and mechanisms of action. They are 
effective against the osteolytic component of hypercalcemia, 
but do not alter renal tubular reabsorption of calcium, and there-
fore are relatively ineffective when the latter is a major causa-
tive factor. 
The only bipbosphonate currently approved and on sale in the 
United States is also the least useful in hypercalcemia: etidro-
nate (EHDP) or Didronel®. It is ineffective against hyper-
calcemia when given orally but is effective intravenously. Sev-
eral other biphosphonates have had considerable testing in 
Europe and generally seem to be more effective than etidronate. 
For example, clodronate (dichloromethylene bipbosphonate) at 
100 to 300 mg/day for up to ten days can restore normocalcemia 
in up to 90% of cases. However, relapse may occur rapidly after 
discontinuance of clodronate. Amidronate (APD) (or AHPr BP) 
is very effective when given as two-hour infusions of 15 mg/day 
for up to 10 days. Doses less than 0.25 mg/kg/day are ineffec-
tive. This dmg is efficacious whether or not skeletal metastases 
are present. Importantly, normocalcemia may last for several 
weeks after stopping amidronate, and its toxicity is low, includ-
ing transient fever and lymphopenia. 
Still newer biphosphonates of even greater potency than 
amidronate are being tested abroad, and some of them are being 
tested in clinical trials in the United States. It seems likely that 
within a few years we shall have available extremely potent bi-
phosphonates capable of inducing prolonged normocalcemia in 
cancer patients, and some of these agents may be active orally. It 
is possible that these agents could also reverse or prevent skel-
etal destmction by metastases. 
Potential use of gallium nitrate and WR-2721 in the 
treatment of hypercalcemia and hyperparathyroidism 
Bonjour et al (2) discussed two antihypercalcemic agents that 
are much further from general use than the biphosphonates; gal-
lium nitrate, and WR-2721 (an organic thiophosphate). 
Gallium nitrate has been used for scanning bone and tumors, 
but because of its localization in nonskeletal malignancies, it 
saw further development as a chemotherapeutic agent. During 
initial human studies, investigators occasionally saw transient 
hypocalcemia, apparently caused by gallium nitrate. In vitro 
studies indicated a direct effect of the compound on PTH- or 
lymphokine-stimulated bone resorption, and further clinical in-
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vestigations suggested that it might be an effective antihyper-
calcemic agent in various types of malignancies. A recent, ran-
domized, double-blind study suggested that gallium nitrate is 
effective in lowering the hypercalcemia of malignancy and that 
it may be superior to maximally effective doses of calcitonin. 
The clinical use of gallium nitrate is not yet at hand, because 
proper comparative studies versus other agents, such as meth-
ramycin and the biphosphonates, are not yet available. Further 
studies are also needed to better understand gallium nitrate's 
mechanisms of action. The existing data suggest that gallium ni-
trate or compounds derived therefrom may be very effective in 
the acute treatment of humoral hypercalcemia of malignancy. 
WR-2721 was also developed as a potential cancer therapeutic 
agent to increase the resistance of normal tissues to ionizing 
radiation and alkylating chemotherapeutic agents. Just as 
for gallium nitrate, the hypocalcemic action of WR-2721 was 
noted incidentally during phase I clinical trials. WR-2721 is a 
remarkable compound in that it both decreases the secretion of 
PTH in vitro and in vivo and directly inhibits renal tubular reab-
sorption of calcium. Furthermore, WR-2721 may directly in-
hibit osteoclastic bone resorption. Some evidence suggests that 
WR-2721 is less potent than biphosphonates or gallium nitrate, 
but more clinical studies are necessary. It is not yet clear 
whether WR-2721 can inhibit secretion of the PTH-related pep-
tide from tumors, but if it can it would have remarkable triple 
efficacy in treating the humoral hypercalcemia of malignancy. 
Just as for gallium nitrate, the very fact that WR-2721 has its 
known effects greatly encourages the search for related com-
pounds that may be highly effective in treating hypercalcemia of 
multiple causes. 
Aluminum-Associated Renal Osteodystrophy 
Therapy of aluminum-related bone disease 
Malluche and Faugere (3) described the syndromes of bone 
disease related to skeletal aluminum accumulation that can oc-
cur in patients undergoing chronic hemodialysis. The aluminum 
is ingested as aluminum hydroxide-containing phosphate-bind-
ing antacid gels or enters from contaminated dialysis solutions. 
Excess bone aluminum may be demonstrable in nearly half of 
patients on chronic dialysis and can occur even in mild to moder-
ate renal failure. In particular, stainable aluminum gathers at the 
interface between unmineralized bone matrix (osteoid) and min-
eralized bone, and it appears to impair the mineralization pro-
cess. Clinical manifestations of aluminum-associated bone dis-
ease include bone pain, fractures, and hypercalcemia. The latter 
must be carefuly differentiated from the hypercalcemia of "ter-
tiary" hyperparathyroidism, because parathyroidectomy may 
only aggravate aluminum-associated bone disease. 
Malluche and Faugere (3) discussed chelation therapy with 
the iron-binder, deferoxamine (Desferal®), which also binds 
aluminum. Deferoxamine binds circulating aluminum ion, 
which is then removed during dialysis. The lowered plasma alu-
minum level reverses the blood-bone concentration gradient, 
and thus allows aluminum to diffuse out of bone. Important 
reductions in bone aluminum can follow several months 
of treatment. 
The histologic manifestations of aluminum-associated bone 
disease vary from so-called "aplastic" or adynamic bone (no ac-
tive bone formation or resorption, and no excess osteoid) to 
florid osteomalacia. In all cases he has treated, Dr. Malluche 
thought that aluminum chelation yielded improvement, 
although reminding us that whatever other type of renal 
osteodystrophy preceded or accompanied the aluminum ac-
cumulation would remain or emerge. 
Deferoxamine therapy has serious side effects, potentially in-
cluding hypotension, angina, and ocular damage. Because of 
this and the difficulties in selecting cases for chelation therapy, 
the treatment is best undertaken only after appropriate studies on 
iliac crest bone biopsies and consultation with a nephrologist ex-
perienced in use of the drag. More long-term studies are needed 
to establish firmly the safety and effectiveness of deferoxamine 
in renal osteodystrophy. 
Osteoporosis 
Of all problems related to bone and calcium metabolism, the 
clinical and economic impact of late-life and postmenopausal 
osteoporosis is the greatest. While acute care of hip fracture 
alone costs several billion dollars per year in the United States, 
the worldwide cost in human suffering and national resources is 
incalculable. While we have made dramatic progress toward un-
derstanding the causes of bone loss, physicians have been fms-
trated by the few treatment options available. In particular, they 
are impatient with the lack of treatments to increase bone mass, 
rather than just slow its loss. In this part of the session, we 
focused on new ways to deliver old treatments (transdermal es-
trogen) and preliminary reports on efficacy of two methods to 
increase bone mass (fluoride and PTH). 
New methods of administration of estrogens 
Lindsay (4) outlined trends in estrogen prescription over re-
cent years and highlighted controversies over risks and benefits 
of estrogen treatment after the menopause. Estrogen clearly re-
tards or even stops bone loss after the menopause but increases 
bone mass little if at all. Estrogen therapy may also decrease the 
risk of cardiovascular disease, but on the other hand the risk of 
endometrial carcinoma is increased. While simultaneous use of 
a progestin, with endometrial shedding, seems to eliminate that 
risk, the relative effects on cardiovascular risk and bone mass 
remain unclear. 
Similarly, delivery of estrogen transdermally bypasses the 
liver and reduces certain estrogen effects mediated by the liver 
(eg, increased plasma binding proteins and clotting factors). It is 
not yet known if transdermal estrogen is cardioprotective or if its 
salutary effect on bone equals that of oral estrogen. Trials in os-
teoporosis are under way, but it will be a long time before all the 
answers are in on how best to give estrogen, to whom, and for 
how long. The transdermal route for estrogen is likely to be 
available soon as a treatment altemative. 
The role of sodium fluoride in the treatment of osteoporosis 
Current studies with sodium fluoride (NaF) were summarized 
by Riggs et al (5). It has been known for many years that skeletal 
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fluorosis can result in sclerotic bones, but only over the last five 
years have there been two long-term, placebo-controlled trials 
of NaF in established osteoporosis, one at the Mayo Clinic, and 
one at Henry Ford Hospital. The authors described preliminary 
data from the Mayo study, which is nearing completion. In brief, 
more than half of the patients taking NaF have had increased 
lumbar spine bone mineral density, but NaF had no effect at all 
on appendicular (cortical) bone mass. The drag therefore may 
be of benefit only to those primarily suffering from the crash 
fracture syndrome. Furthermore, there was a significant minor-
ity who did not respond to NaF, and the treatment was associated 
with a fairly high incidence of various side effects, including 
gastric irritation and bleeding, anemia, and lower-extremity 
pain from stress fractures. Data on fracture rates are still being 
obtained. Obviously, antifracture efficacy of NaF must be deter-
mined before it can be approved for general use. Because the 
bone generated during NaF treatment is stractually abnormal, it 
is possible (but unlikely) that the increased bone mass would not 
stop fracturing. The bone community eagerly awaits definitive 
reports from both of the large trials to see if NaF will find a major 
role in treatment of osteoporosis. 
Parathyroid peptide (hPTH 1-34) in the treatment of 
osteoporosis 
Reeve et al (6) gave an update on clinical trials with a seem-
ingly paradoxical treatment for osteoporosis: parenteral syn-
thetic PTH fragment 1-34 [hPTH-(l-34)]. In hyperparathyroid 
diseases, endogenous PTH generally causes bone loss, but inter-
mittent elevation of PTH in animals by injection sometimes 
causes osteosclerosis. Reeve and colleagues have taken advan-
tage of the fact that PTH can increase bone formation as well as 
resorption. They have administered hPTH-(l-34) as once-daily 
injections alone or in combination with 1,25-dihydroxyvitamin 
D or estrogen. The latter compounds were given to enhance cal-
cium absorption, which does not reliably follow intermittent 
elevations of plasma PTH. 
When daily hPTH-(l-34) was given alone, they saw increased 
trabecular volume in iliac crest biopsies but neutral calcium bal-
ance and decreased femoral bone mass. In early studies, alter-
nating hPTH-(l-34) for six weeks with 1,25-dihydroxyvitamin 
D for six weeks appeared to increase spinal bone mass, as did 
combination of hPTH-(l-34) with estrogen. 
This work is important for what it teaches about physiology of 
bone, but application of hPTH-(l-34) to clinical practice in these 
complex regimens is problematic. The peptide is very expensive 
and must be given parenterally. Further, the difficulty in finding 
a simple, safe, and effective regimen is somewhat discouraging. 
At a minimum, this work shows that bone formation can be 
increased by something other than fluoride and certainly will 
encourage continued research. 
Final Note 
This session showed that safe, effective acute therapy for life-
threatening hypercalcemia is now available and will soon be 
even better, that altemative methods for administering estrogen 
will soon be out, and that effective treatments to increase bone 
mass (at least in the spine) are feasible and may reach clinical 
use within the next five years. If advances in the coming decade 
match those of the last, it may not be too mucb to hope that death 
and morbidity from several bone and calcium disorders could be 
virtually eliminated before the end of the century. 
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